Acquisition is expected to strengthens Thermo Fisher’s position in delivering clinical information to pharma and biotech customers.
The rise of AI-powered health apps that claim to diagnose conditions in real time is transforming how we approach healthcare. From symptom checkers to wearable ECG monitors and AI stethoscope apps, these tools promise early diagnoses and personalized healthcare at our fingertips. What if they go wrong?
The companies have reached a long-term agreement allowing customers to use software, data, technology, and service offerings from Veeva and IQVIA together.
FHIR (Fast Healthcare Interoperability Resources) is an open standard designed to streamline data sharing within national healthcare systems and across systems in different countries. Its introduction aims to bring more consistency to patient care, ensuring that no matter where healthcare professionals (HCPs) are located, they can access the same up-to-date information on medications and their patients.
This silent crisis has dire consequences. Patients face delays, errors increase and the entire system suffers. This cannot continue. But in the face of such crippling challenges, how can healthcare practices look to improve the interoperability of their systems?
MTI Viewpoint: I expect fundamental changes to our medical device ecosystem; not all companies will survive them. The ability to consistently use AI will also determine who will be among the survivors and even the winners. AI will not only be part of the devices but also an internal tool.
For over four decades, the medical device industry has wrestled with fragmented data exchange and proprietary integrations. HL7’s Device Interoperability FHIR Accelerator initiative offers a vendor-neutral framework to finally achieve plug-and-play interoperability—unlocking scalable, AI-powered MedTech innovation and improving patient outcomes.
AI’s reach depends on the environments in which it operates as well as how it is developed and deployed, highlighting a fundamental debate on whether we should push for regulation or opt for free-market-driven deregulation.
Evolving regulations and market requirements have kept medtech companies on their toes for years. EU MDR, for example, has been a top priority and now, more companies are moving toward EU MDR sustainability. As we look ahead to an unpredictable year in medtech, three areas stand out as opportunities for medtech to drive meaningful progress. AI, recall management, and regulatory intelligence could be key differentiators for medtechs — if approached strategically.
According to CDER Director Patrizia Cavazzoni, CDER’s new Center for Real-World Evidence Innovation represents a major step forward in efforts to unlock the full potential of RWD to inform clinical and regulatory decisions.